Abelacimab Could Dissolve Blood Clots Effectively

0

“Patients who undergo knee replacement routinely receive anti-clotting treatment with enoxaparin or other anticoagulant medications that require daily administration,” Jeffrey Weitz said.


“With a single injection of abelacimab after surgery, we found much better protection against clots in the veins in the leg compared with enoxaparin, one of the current standards of care.”

Loading...

Patients were closely monitored for symptoms or signs of clotting or bleeding and underwent an x-ray of the veins of the operated leg to detect any possible clot formation.

“This success of abelacimab in this study provides the foundation for its use for prevention of stroke in patients with atrial fibrillation and for treatment of deep-vein thrombosis and pulmonary embolism, clots in the veins of the leg and clots in the lung, in patients with cancer,” said Weitz.

Abelacimab binds to both the inactive and activated forms of factor XI, thereby halting clot formation.

Loading...

Factor XI was found to be a key driver of clot formation after surgery, Weitz said, adding that the fact that abelacimab was more effective than enoxaparin, which inhibits clotting factors downstream to factor XI, highlights the importance of factor XI in clot formation.

“We expect factor XI to be a safer target for new anticoagulants than the targets of currently available anticoagulants because patients with congenital factor XI deficiency are at reduced risk for clots but rarely have spontaneous bleeding,” he said.

Weitz said new anti-clotting medications are often tested first on patients undergoing orthopedic surgery. Different doses of the drug can be evaluated to identify those that are both effective and safe compared with the standard of care such as enoxaparin.

Loading...

Source: Medindia

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

Loading...

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Loading...
Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment